Cargando…

Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer

INTRODUCTION: Unclassified variants (UVs) of unknown clinical significance are frequently detected in the BRCA2 gene. In this study, we have investigated the potential pathogenic relevance of the recurrent UV S384F (BRCA2, exon 10). METHODS: For co-segregation, four women from a large kindred (BN326...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wappenschmidt, B, Fimmers, R, Rhiem, K, Brosig, M, Wardelmann, E, Meindl, A, Arnold, N, Mallmann, P, Schmutzler, RK
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242149/ https://www.ncbi.nlm.nih.gov/pubmed/16168123 http://dx.doi.org/10.1186/bcr1291

Ejemplares similares

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

Analysis of 30 Putative BRCA1 Splicing Mutations in Hereditary Breast and Ovarian Cancer Families Identifies Exonic Splice Site Mutations That Escape In Silico Prediction
por: Wappenschmidt, Barbara, et al.
Publicado: (2012)

Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature
por: Herold, Natalie, et al.
Publicado: (2018)

Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire
por: Herold, Natalie, et al.
Publicado: (2022)

Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
por: Ataseven, Beyhan, et al.
Publicado: (2020)

Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia‐like phenotype, and no chromosome fragility
por: Keupp, Katharina, et al.
Publicado: (2019)

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study
por: Rhiem, Kerstin, et al.
Publicado: (2012)

Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer
por: Wappenschmidt, Barbara, et al.
Publicado: (2020)

Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer
por: Rolfes, Muriel, et al.
Publicado: (2022)

Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
por: Krassuski, Lisa Marlene, et al.
Publicado: (2021)

Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report
por: Bredow, Kathrin, et al.
Publicado: (2022)

RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families
por: Schnurbein, Gioia, et al.
Publicado: (2013)

Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2023)

Gene panel testing of 5589 BRCA1/2‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer
por: Hauke, Jan, et al.
Publicado: (2018)

Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study
por: Dick, Julia, et al.
Publicado: (2022)

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
por: Engel, Christoph, et al.
Publicado: (2018)

Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2021)

Identification and refinement of two regions on chromosomal arm 15q involved in breast cancer progression
por: Rhiem, K, et al.
Publicado: (2001)

“You Always Have It in the Back of Your Mind”—Feelings, Coping, and Support Needs of Women with Pathogenic Variants in Moderate-Risk Genes for Hereditary Breast Cancer Attending Genetic Counseling in Germany: A Qualitative Interview Study
por: Stracke, Claudia, et al.
Publicado: (2022)

Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2022)

Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study
por: Isselhard, A., et al.
Publicado: (2020)

Has BRICS lost its appeal? The foreign policy value added of the group
por: Brosig, Malte
Publicado: (2021)

Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers
por: Borde, Julika, et al.
Publicado: (2022)

Large Deletions in the BRCA1 Gene Are Not Common in a Set of Familial German Breast Cancer Patients
por: Maringa, M., et al.
Publicado: (1999)

Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial
por: Kiechle, Marion, et al.
Publicado: (2016)

384 Alterations in the fungal microbiome in ulcerative colitis
por: Jangi, Sushrut, et al.
Publicado: (2023)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites
por: Digennaro, M., et al.
Publicado: (2017)

Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)
por: Kiechle, Marion, et al.
Publicado: (2016)

Strong Hereditary Predispositions to Colorectal Cancer
por: Hryhorowicz, Szymon, et al.
Publicado: (2022)

Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers – an interventional randomized controlled multicenter trial (LIBRE-1)
por: Kiechle, Marion, et al.
Publicado: (2017)

BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome
por: Ewald, Ingrid Petroni, et al.
Publicado: (2016)

Emploi du solde du compte 20.384
por: Germain, C
Publicado: (1979)

Requirement for Serine-384 in Caspase-2 processing and activity
por: Zamaraev, Alexey V., et al.
Publicado: (2020)

Index to Hydrobiologia Volumes 251-384 (1993-1999)
Publicado: (2000)

Spine Biomechanics in the Work of Aristotle (384 – 322 BC)
por: Tsagkaris, Christos, et al.
Publicado: (2022)

BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study
por: Frank, Bernd, et al.
Publicado: (2007)

Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study
por: Burwinkel, Barbara, et al.
Publicado: (2006)

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families
por: NOVAKOVIĆ, SRDJAN, et al.
Publicado: (2012)

Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer
por: Buleje, Jose, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d3i45t8e55edm8gmdca45fg5a7